Henry Schein Inc
$ 76.04
-0.47%
02 Jun - close price
- Market Cap 8,703,240,000 USD
- Current Price $ 76.04
- High / Low $ 76.79 / 75.84
- Stock P/E 23.08
- Book Value 28.54
- EPS 3.31
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.09 %
- 52 Week High 89.29
- 52 Week Low 61.95
About
Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.
Analyst Target Price
$87.21
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-24 | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-02-25 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-13 | 2023-08-07 |
| Reported EPS | 1.32 | 1.34 | 1.38 | 0.7 | 0.88 | 1.19 | 1.22 | 1.23 | 1.1 | 0.66 | 1.32 | 1.31 |
| Estimated EPS | 1.22 | 1.3 | 1.28 | 0.92 | 0.9 | 1.2089 | 1.17 | 1.22 | 1.01 | 0.69 | 1.32 | 1.28 |
| Surprise | 0.1 | 0.04 | 0.1 | -0.22 | -0.02 | -0.0189 | 0.05 | 0.01 | 0.09 | -0.03 | 0 | 0.03 |
| Surprise Percentage | 8.1967% | 3.0769% | 7.8125% | -23.913% | -2.2222% | -1.5634% | 4.2735% | 0.8197% | 8.9109% | -4.3478% | 0% | 2.3438% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.23 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HSIC
2026-06-01 21:49:32
Wolfe Research initiated coverage on Danaher Corp. (NYSE:DHR) with a Peerperform rating, setting a fair value range of $165 to $185 per share, which is around the current trading price. The valuation is based on an 18 to 20 times 2027 earnings per share estimate, incorporating the upcoming Masimo acquisition. The firm notes that Danaher, a prominent player in the Life Sciences Tools & Services industry, has a "GOOD" financial health score according to InvestingPro metrics.
2026-06-01 21:07:27
Wolfe Research has initiated coverage on Danaher Corp. (NYSE:DHR) with a Peerperform rating and a fair value range of $165 to $185 per share. The valuation incorporates the upcoming Masimo acquisition, expected to close on July 1, and projects a 15 to 20 cents first-year accretion in 2027. Danaher, with a market cap of $127.6 billion, maintains a "GOOD" financial health score, and its stock currently trades within the firm's target range.
2026-06-01 07:26:53
Henry Schein (HSIC) recently announced a significant governance shift with William K. Daniel becoming the independent Chairman and shareholders approving majority voting for director elections. This, combined with a reaffirmed value-creation plan targeting $125 million in operating income improvement by 2026, aims to boost investor confidence through increased focus on governance, efficiency, and innovation. The article suggests that while governance updates are positive, investors should also monitor competitive pricing pressures and execution on the operating income goals.
2026-06-01 07:26:52
Henry Schein, Inc. announced a significant governance shift with William K. Daniel becoming the independent Chairman and shareholders approving majority voting for director elections. This, combined with a reaffirmed value-creation plan targeting $125 million in operating income improvement by 2026, aims to enhance efficiency and innovation. Investors will closely watch if these changes support the company's financial goals, despite potential competitive pricing pressures.
2026-05-31 17:37:52
This article provides a Q1 2026 earnings preview for Henry Schein. It anticipates the company's financial performance and key metrics ahead of its official earnings report. Investors and analysts will be looking for insights into revenue, profitability, and future guidance for the dental and medical product distributor.
2026-05-31 05:07:47
Henry Schein (NASDAQ:HSIC) executives affirm the company is on track to meet its 2026 commitments and value-creation plan, anticipating a $125 million net run-rate operating income improvement by the end of 2026. The company sees steady demand in the U.S. dental market, driven by employment and insurance coverage, and is focusing on simplifying operations, scaling for growth, and investing in new technologies, products, and a disciplined capital allocation strategy. CEO Fred Lowery and CFO Ron South highlighted improvements in the dental business, growth in home solutions, and strategic initiatives to enhance gross profit and operating efficiency.
